Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Other Operating Expenses (2021 - 2024)

Historic Other Operating Expenses for Relay Therapeutics (RLAY) over the last 4 years, with Q2 2024 value amounting to -$11.4 million.

  • Relay Therapeutics' Other Operating Expenses fell 42853.16% to -$11.4 million in Q2 2024 from the same period last year, while for Mar 2025 it was -$11.4 million, marking a year-over-year decrease of 5686.11%. This contributed to the annual value of -$13.2 million for FY2024, which is 10563.69% down from last year.
  • Per Relay Therapeutics' latest filing, its Other Operating Expenses stood at -$11.4 million for Q2 2024, which was down 42853.16% from -$1.8 million recorded in Q1 2024.
  • In the past 5 years, Relay Therapeutics' Other Operating Expenses ranged from a high of $134.9 million in Q2 2021 and a low of -$11.4 million during Q2 2024
  • Its 4-year average for Other Operating Expenses is $8.2 million, with a median of -$1.2 million in 2023.
  • Per our database at Business Quant, Relay Therapeutics' Other Operating Expenses crashed by 136124.4% in 2022 and then soared by 8039.64% in 2023.
  • Relay Therapeutics' Other Operating Expenses (Quarter) stood at $836000.0 in 2021, then tumbled by 1361.24% to -$10.5 million in 2022, then surged by 80.4% to -$2.1 million in 2023, then plummeted by 450.27% to -$11.4 million in 2024.
  • Its Other Operating Expenses was -$11.4 million in Q2 2024, compared to -$1.8 million in Q1 2024 and -$2.1 million in Q4 2023.